230 related articles for article (PubMed ID: 15033359)
1. Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold.
Jespers L; Schon O; James LC; Veprintsev D; Winter G
J Mol Biol; 2004 Apr; 337(4):893-903. PubMed ID: 15033359
[TBL] [Abstract][Full Text] [Related]
2. The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains.
Honegger A; Malebranche AD; Röthlisberger D; Plückthun A
Protein Eng Des Sel; 2009 Mar; 22(3):121-34. PubMed ID: 19136675
[TBL] [Abstract][Full Text] [Related]
3. Energy-based analysis and prediction of the orientation between light- and heavy-chain antibody variable domains.
Narayanan A; Sellers BD; Jacobson MP
J Mol Biol; 2009 May; 388(5):941-53. PubMed ID: 19324053
[TBL] [Abstract][Full Text] [Related]
4. Improving solubility and refolding efficiency of human V(H)s by a novel mutational approach.
Tanha J; Nguyen TD; Ng A; Ryan S; Ni F; Mackenzie R
Protein Eng Des Sel; 2006 Nov; 19(11):503-9. PubMed ID: 16971398
[TBL] [Abstract][Full Text] [Related]
5. Structure of a non-camelized human M12-V(H) domain at 1.5A resolution.
Gaur RK
J Struct Biol; 2005 Oct; 152(1):84-9. PubMed ID: 16183303
[TBL] [Abstract][Full Text] [Related]
6. Conserved amino acid networks involved in antibody variable domain interactions.
Wang N; Smith WF; Miller BR; Aivazian D; Lugovskoy AA; Reff ME; Glaser SM; Croner LJ; Demarest SJ
Proteins; 2009 Jul; 76(1):99-114. PubMed ID: 19089973
[TBL] [Abstract][Full Text] [Related]
7. The importance of framework residues H6, H7 and H10 in antibody heavy chains: experimental evidence for a new structural subclassification of antibody V(H) domains.
Jung S; Spinelli S; Schimmele B; Honegger A; Pugliese L; Cambillau C; Plückthun A
J Mol Biol; 2001 Jun; 309(3):701-16. PubMed ID: 11397090
[TBL] [Abstract][Full Text] [Related]
8. Solution structure and backbone dynamics of an antigen-free heavy chain variable domain (VHH) from Llama.
Renisio JG; Pérez J; Czisch M; Guenneugues M; Bornet O; Frenken L; Cambillau C; Darbon H
Proteins; 2002 Jun; 47(4):546-55. PubMed ID: 12001233
[TBL] [Abstract][Full Text] [Related]
9. Aggregation-resistant VHs selected by in vitro evolution tend to have disulfide-bonded loops and acidic isoelectric points.
Arbabi-Ghahroudi M; To R; Gaudette N; Hirama T; Ding W; MacKenzie R; Tanha J
Protein Eng Des Sel; 2009 Feb; 22(2):59-66. PubMed ID: 19033278
[TBL] [Abstract][Full Text] [Related]
10. Arginine mutation alters binding of a human monoclonal antibody to antigens linked to systemic lupus erythematosus and the antiphospholipid syndrome.
Lambrianides A; Giles I; Ioannou Y; Mason L; Latchman DS; Manson JJ; Isenberg DA; Rahman A
Arthritis Rheum; 2007 Jul; 56(7):2392-401. PubMed ID: 17599767
[TBL] [Abstract][Full Text] [Related]
11. Rearrangement of the former VL interface in the solution structure of a camelised, single antibody VH domain.
Riechmann L
J Mol Biol; 1996 Jun; 259(5):957-69. PubMed ID: 8683598
[TBL] [Abstract][Full Text] [Related]
12. Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach.
Ewert S; Honegger A; Plückthun A
Biochemistry; 2003 Feb; 42(6):1517-28. PubMed ID: 12578364
[TBL] [Abstract][Full Text] [Related]
13. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the horse V(H) repertoire and comparison with the human IGHV germline genes, and sheep, cattle and pig V(H) sequences.
Almagro JC; Martinez L; Smith SL; Alagon A; Estevez J; Paniagua J
Mol Immunol; 2006 Apr; 43(11):1836-45. PubMed ID: 16337682
[TBL] [Abstract][Full Text] [Related]
15. The role of interface framework residues in determining antibody V(H)/V(L) interaction strength and antigen-binding affinity.
Masuda K; Sakamoto K; Kojima M; Aburatani T; Ueda T; Ueda H
FEBS J; 2006 May; 273(10):2184-94. PubMed ID: 16649995
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of a shark single-domain antibody V region in complex with lysozyme.
Stanfield RL; Dooley H; Flajnik MF; Wilson IA
Science; 2004 Sep; 305(5691):1770-3. PubMed ID: 15319492
[TBL] [Abstract][Full Text] [Related]
17. Intrabody construction and expression III: engineering hyperstable V(H) domains.
Wirtz P; Steipe B
Protein Sci; 1999 Nov; 8(11):2245-50. PubMed ID: 10595527
[TBL] [Abstract][Full Text] [Related]
18. Structural consequences of humanizing an antibody.
Holmes MA; Foote J
J Immunol; 1997 Mar; 158(5):2192-201. PubMed ID: 9036965
[TBL] [Abstract][Full Text] [Related]
19. A peptide mimic of an antigenic loop of alpha-human chorionic gonadotropin hormone: solution structure and interaction with a llama V(HH) domain.
Ferrat G; Renisio JG; Morelli X; Slootstra J; Meloen R; Cambillau C; Darbon H
Biochem J; 2002 Sep; 366(Pt 2):415-22. PubMed ID: 11996668
[TBL] [Abstract][Full Text] [Related]
20. Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework.
Kügler M; Stein C; Schwenkert M; Saul D; Vockentanz L; Huber T; Wetzel SK; Scholz O; Plückthun A; Honegger A; Fey GH
Protein Eng Des Sel; 2009 Mar; 22(3):135-47. PubMed ID: 19188138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
